Published on 6 Dec 2021 on Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple...
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector recorded weekly losses, reversing course from the previous week's advance.
Regulatory decisions scheduled for the week turned in mixed outcomes. VBI Vaccines Inc. (NASDAQ: VBIV) and Merck & Co., Inc. (NYSE: MRK) received greenlights from the FDA, the former for its PreHevbrio, a preventative treatment for hepatitis B virus infection, and latter for an expanded label for its cancer drug Keytruda.
NASDAQ.ONCS price evolution
NASDAQ.OBSV price evolution
NASDAQ.SURF price evolution
NASDAQ.RETA price evolution
NASDAQ.ATOS price evolution
NASDAQ.JAGX price evolution
NASDAQ.DARE price evolution
NASDAQ.BGNE price evolution
NASDAQ.ARVN price evolution
NASDAQ.APLT price evolution
NASDAQ.APDN price evolution
NASDAQ.IDYA price evolution
NASDAQ.IPHA price evolution
NASDAQ.KURA price evolution
NASDAQ.KPTI price evolution
NYSE.ATNM price evolution
NYSE.ADCT price evolution
NASDAQ.MOR price evolution
NASDAQ.MRUS price evolution
NASDAQ.MGTX price evolution
NASDAQ.INFI price evolution
NASDAQ.CYTK price evolution
NASDAQ.PBYI price evolution
NASDAQ.DTIL price evolution
NASDAQ.BYSI price evolution
NASDAQ.IMGN price evolution
NASDAQ.NKTR price evolution
NASDAQ.INCY price evolution
NASDAQ.ALNY price evolution
NASDAQ.AGIO price evolution
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free